Biomarkers | Country | Study | Tumor | No. patients | Therapy strategy | CR + PR Rate | P-valuea |
---|---|---|---|---|---|---|---|
(Stage) | or Median | ||||||
Biomarkers of neoadjuvant chemotherapy | |||||||
 Primary tumor size (cm) | |||||||
   > 5 (vs. 4–5) [26] | China | Prospective | CC | 157 | Cis + VCR + BLM + Surg | 72% (vs. 88%) | 0.018 |
IB/IIA | |||||||
   ≥ 5 (vs. < 5) [8] | China | Retrospective | CC | 219 | PTX + CBP + Surg | 62% (vs. 56%) | 0.027 |
IB2/IIA2 | |||||||
   > 8 (vs. ≤ 8) [25] | China | RCT | CC | 72 | Cis + MC + 5-FU + Surg | 42% (vs. 75%) | 0.029 |
IB2/IIB | |||||||
 Age (years) | |||||||
   ≥ 35 (vs. < 35) [26] | China | Prospective | CC | 157 | Cis + VCR + BLM + Surg | 83% (vs. 53%) | 0.029 |
IB/IIA | |||||||
   ≥ 35 (vs. < 35) [27] | China | Retrospective | SCC | 851 | Platinum-based + Surg | 81% (vs. 88%) | 0.041 |
IB1/IIB | |||||||
 Blood biomarkers | |||||||
  NLR | Rome | Prospective | CC | 37 | Cis + PTX + Surg | 2.8 (vs. 4.41) | 0.032 |
(response vs. nonresponse) [9] | IB2/IVA | ||||||
  PLR | Rome | Prospective | CC | 37 | Cis + PTX + Surg | 1.48 × 105 (vs. 1.78 × 105) | 0.026 |
    (response vs. nonresponse) [9] | IB2/IVA | ||||||
   SIRI | China | Retrospective | CC | 187 | Cis + PTX + Surg | 0.75 vs. 1.29 | 0.001 |
    (response vs. nonresponse) [32] | IB2/IIA2 | ||||||
   SCC-Ag > 3.5 ng/mL (vs. ≤ 3.5) [33] | China | Retrospective | CC | 286 | Cis + PTX/Cis + CPT | 66% (vs. 82%) | 0.010 |
IB1/IIIB | |||||||
 Other biomarkers | |||||||
  HIF-1α ≥ 6b (vs. ≤ 4b) [29] | China | Retrospective | CC | 59 | Cis + PTX | 75% (vs. 95%) | 0.025 |
IIB/IIIB | |||||||
  PRMT1 ≥ 6b (vs. ≤ 4b) [34] | Japan | Retrospective | CC | 53 | Cis + PTX | 40% (vs. 69.6%) | 0.033 |
IIIB | |||||||
  Galectin-1 | China | Prospective | CC | 35 | Cis + 5-FU + MC | 8.0 vs. 12.0 | 0.020 |
   (response vs. nonresponse) [35] | IB2-IIA2 | ||||||
  Integrin α5β1 | China | Prospective | CC | 35 | Cis + 5-FU + MC | 6.0 vs. 8.0 | 0.005 |
   (response vs. nonresponse) [35] | IB2-IIA2 | ||||||
  XPA ≥ 4b (vs. ≤ 3b) [36] | Japan | Retrospective | CC | 56 | Cis + PTX | 41% (vs. 88%) | 0.001 |
IIIA-IIIB | |||||||
  UCP2 ≥ 8b (vs. ≤ 6b) [37] | Japan | Retrospective | CC | 58 | Cis + PTX | 49% (vs. 76%) | 0.041 |
IIIA-IIIB | |||||||
  TBX2 ≥ 6b (vs. ≤ 4b) [38] | Japan | Retrospective | CC | 46 | Cis + PTX | 36% (vs. 76%) | 0.009 |
IIIA-IIIB | |||||||
  EGFL7 ≥ 8b (vs. ≤ 6b) [28] | Japan | Retrospective | CC | 63 | Cis + PTX | 19% (vs. 86%) | 0.001 |
IIIA-IIIB | |||||||
Biomarkers of immunotherapy | |||||||
  TMB-high (vs. TMB-low) [39] | China | Retrospective | CC | 32 | Cam + Apa | 83% (vs. 43%) |  < 0.050 |
M/R/P | |||||||
  PD-L1 ≥ 1% (vs. < 1%) [40] | America | Phase I trial | Solid tumor | 132 | Keytruda | 22% (vs. 4%) | 0.021 |
  MMRd/MSI-H (vs. MMRp/MSS) [41] | Korea | Retrospective | Gynecologic cancers | 1093 | Keytruda + OPDIVO | 29% (vs. 12%) |  < 0.050 |